Patents by Inventor Michael John Crimmin

Michael John Crimmin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5910609
    Abstract: Compounds of general Formula I: ##STR1## are presented which have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and the promotion of wound healing. Representative diseases involving include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption disease and tumor invasion.
    Type: Grant
    Filed: April 5, 1995
    Date of Patent: June 8, 1999
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Colin Campion, Alan Hornsby Davidson, Jonathan Philip Dickens, Michael John Crimmin
  • Patent number: 5821262
    Abstract: A compound of formula (I): ##STR1## wherein: R.sup.1 represents a (C.sub.1 -C.sub.6)alkyl, phenyl, substituted phenyl, or heterocyclyl group; R.sup.2 represents a (C.sub.1 -C.sub.6)alkyl group; R.sup.3 represents:(I) the side chain of arginine, lysine, tryptophan, histidine, serine, threonine, or cysteine, in which any polar amino, hydroxy, mercapto, guanidyl, imidazolyl or indolyl group is rendered substantially non-polar by substitution at the polar N-, O- or S-atom; or(ii) the side chain of aspartic or glutamic acid, in which side chain the carboxylic acid group is amidated;R.sup.4 represents hydrogen or a (C.sub.1 -C.sub.6)alkyl or phenyl (C.sub.1 -C.sub.6)alkyl group; R.sup.5 represents hydrogen or and n is 0, 1 or 2; or substituted phenyl groups; or a salt solvate or hydrate thereof. Compositions containing compound (I) and methods for treatment of diseases or conditions mediated by TNF or MMPs in mammals.
    Type: Grant
    Filed: October 28, 1996
    Date of Patent: October 13, 1998
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Michael John Crimmin, Raymond Paul Beckett
  • Patent number: 5700838
    Abstract: Compounds of formula (I) have matrix metalloproteinase inhibitory activity, wherein R.sub.2 represents a group R.sub.6 --A-- wherein A represents a divalent straight or branched, saturated or unsaturated hydrocarbon chain of up to 6 C atoms which may be interrupted by an O or S atom, and R.sub.6 represents hydrogen or an optionally substituted phenyl, cycloalkyl or cycloalkenyl group; R.sub.3 represents a group R.sub.7 --(B).sub.n -- wherein n is 0 or 1, B represents a divalent straight or branched, saturated or unsaturated hydrocarbon chain of up to 6 C atoms which may be interrupted by an O or S atom, and R.sub.7 is --CONHOH, carboxyl, esterified or amidated carboxyl, cycloalkyl, cycloalkenyl, heterocyclyl, phenyl, naphtyl, or substituted phenyl or naphtyl in which the substituent(s) are selected from phenyl, hydroxy, C.sub.1 -C.sub.6 alkoxy, benzyloxy, or R.sub.8 --(C.dbd.O)--(C.sub.1 -C.sub.6 alkyl)--O-- wherein R.sub.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: December 23, 1997
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Jonathan Philip Dickens, Michael John Crimmin, Raymond Paul Beckett
  • Patent number: 5696082
    Abstract: Compounds of general formula (I) wherein X is --CONHOH or --CO.sub.2 H, principally characterised by the presence in substituent R.sub.3 and/or R.sub.4 of a group of formula (II) are inhibitors of matrix metalloproteinases and inhibitors of the production of turnout necrosis factor.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: December 9, 1997
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Michael John Crimmin, Andrew Paul Ayscough, Raymond Paul Beckett
  • Patent number: 5691382
    Abstract: The present invention is directed to the method of inhibiting the release of tumor necrosis factor (TNF) in a condition mediated by TNF by administration of certain hydroxamic add derivatives, also known as matrix metalloproteinase inhibitors, and thus the method of this invention is useful in the management of diseases or conditions mediated by TNF.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 25, 1997
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Michael John Crimmin, William Alan Galloway, Andrew John Hubert Gearing
  • Patent number: 5652262
    Abstract: Compounds of general formula (I) wherein R.sup.1 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl, phenyl(C.sub.1 -C.sub.6)alkyl, C.sub.1 -C.sub.6 alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl(C.sub.1 -C.sub.6)alkylthiomethyl or heterocyclylthiomethyl group; or R.sup.1 represents --S--R.sup.x wherein R.sup.x represents a group .alpha.; R.sup.2 represents a hydrogen atom or a C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkenyl, phenyl(C.sub.1 -C.sub.6)alkyl, cycloalkyl(C.sub.1 -C.sub.6)alkyl, or cycloalkenyl(C.sub.1 -C.sub.6)alkyl; R.sup.3 represents an amino acid side chain or a C.sub.1 -C.sub.6 alkyl, benzyl, (C.sub.1 -C.sub.6)alkoxybenzyl, benzyloxy(C.sub.1 -C.sub.6)alkyl or benzyloxybenzyl group; R.sup.4 represents a hydrogen atom or a methyl group; R.sup.5 represents a group (CH.sub.2).sub.n A; or R.sup.4 and R.sup.5 together represent a group .beta.; Q represents CH.sub.
    Type: Grant
    Filed: December 1, 1995
    Date of Patent: July 29, 1997
    Assignee: British Biotech Pharmaceutical, Ltd.
    Inventors: Michael John Crimmin, Raymond Paul Beckett, Mark Hampton Davis
  • Patent number: 5643964
    Abstract: Compounds of Formula (I) wherein R.sub.2 represents a group R.sub.6 --A-- wherein A represents a divalent straight or branched, saturated or unsaturated hydrocarbon chain of up to 6 C atoms which may be interrupted by an O or S atom, and R.sub.6 represents hydrogen or an optionally substituted phenyl, cycloalkyl or cycloalkenyl group; R.sub.3 represents the characterizing side chain of a natural alpha amino acid other than proline, and in which any polar substituents are optionally protected; R.sub.4 represents hydrogen or methyl; R.sub.5 represents hydrogen, C.sub.1 -C.sub.6 alkyl or a group D-(C.sub.1 -C.sub.6 alkyl) wherein D represents hydroxy, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, acylamino, optionally substituted phenyl, or a heterocyclic group, NH.sub.2, or a mono- or di-(C.sub.1 -C.sub.6 alkyl) amine or a heterocyclic group; or R.sub.3 and R.sub.
    Type: Grant
    Filed: January 23, 1995
    Date of Patent: July 1, 1997
    Assignee: British Biotech Pharmaceuticals Limited
    Inventors: Jonathan Philip Dickens, Michael John Crimmin, Raymond Paul Beckett